Novo Nordisk A/S vs Texas Instruments Incorporated — how do they compare? Novo Nordisk A/S trades at $38.47 (market cap $165.31B), while Texas Instruments Incorporated trades at $284.17 (market cap $263.20B). The key difference: Texas Instruments Incorporated is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Texas Instruments Incorporated for 76 Days on average.
| NVO | TXN | |
|---|---|---|
Market Cap | $165.31B | $263.20B |
Volume | 11,432,838 | 5,850,256 |
Sector | Health | Technology |
52-Week High | $63.98 | $332.35 |
52-Week Low | $35.29 | $153.33 |
Typical Hold Time | 116 Days | 76 Days |
Enterprise Value | $179.56B | $270.25B |
Dividend Yield | 4.71% | 2.11% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Texas Instruments (TXN) trades at $288.94, down 2.82% on the day, amid a broader semiconductor sell-off. The stock maintains a bullish technical outlook with strong moving average signals and key support at $286. Fundamentally, revenue and earnings are recovering, with Q2 2026 EPS beating expectations at $2.14 versus $1.91, driven by data center sales growth and margin expansion. The company's net income margin stands at 31.11%, with robust cash flow from operations of $7.15 billion in 2025.
The outlook for TXN is positive, supported by accelerating data center demand, AI infrastructure investments, and a consensus price target of $325 implying 12% upside. Risks include premium valuation with a P/E of 43.8 and rising debt-to-asset ratio of 40.61% in 2025. Analyst sentiment is bullish with 47.69% buy ratings, though competitive pressures and cyclical semiconductor demand pose headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →